RICE ORS WITH HIV ASSOCIATED DIARRHEA

与 HIV 相关的腹泻的大米或其他药物

• 批准号: 2017590
• 负责人: DAVID A SACK
• 金额: $ 4.86万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-01 至 1999-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2017590
• 关键词: AIDS therapy; HIV infections; adult human (21+); body fluid balance therapy; body water dehydration; body weight; clinical research; clinical trials; diarrhea; diet therapy; food science /technology; human subject; human therapy evaluation; intravenous administration; nutrition related tag; opportunistic infections; oral administration; outcomes research; rice; secondary infection

DESCRIPTION (Taken from application) The long term goal is to maximize the appropriate use of oral rehydration therapy as a simple and inexpensive treatment for dehydration in adults with HIV-associated diarrhea. Using rice-based oral rehydration solution (RB-ORS), dehydrated patients with HIV-associated diarrhea should be able to replace fluids, maintain hydration and electrolyte balance and thereby a) lessen the need for hospitalization and intravenous fluids, b) increase the ability of the patients to live independently, c) lessen diarrhea-associated morbidity by decreasing the volume and duration of purging. Specifically, the study should show a) that RB-ORS will effectively rehydrate and maintain hydration in most HIV infected adults with diarrhea, b) that the rehydration treatment with RB-ORS will have no untoward effects, and c) that patients will prefer RB-ORS as a means of rehydration compared to I.V. treatment. This will be a randomized clinical trial of 30 patients with HIV-associated diarrhea who are felt to require intravenous fluids by their physician because of objective signs of dehydration. They will be randomized to receive either RB-ORS (n=20) or intravenous rehydration (n=10), and they will receive this treatment while being monitored in Johns Hopkins Hospital General Clinical Research Center for two days. Using objective measures of rehydration (body weight, fluid intake and output, serial hematocrit and total protein measurements, and serial bioimpedence), the success rate and the rate of improvement with the two treatments will be documented. Patients who receive RB- ORS but are not rehydrated will be placed on I.V.'s. If a high proportion of the patients can be successfully rehydrated and maintained with RB-ORS, the usefulness of RB-ORS will be established.

描述（取自应用程序） 长期目标是最大化适当使用口服补液 治疗是一种简单且廉价的疗法，用于成人的脱水 HIV相关的腹泻。 使用基于水稻的口服补液溶液 （RB-or），患有HIV相关腹泻的脱水患者应该能够 更换液体，保持水合和电解质平衡，从而a） 减少住院和静脉输液的需求，b）增加 患者独立生活的能力，c）减少腹泻相关的能力 通过减少清除的体积和持续时间来发病。 具体来说， 该研究应表明a）rb-ors将有效地补水并维护 大多数HIV感染腹泻的成年人的水合，b）补液 用RB-or的治疗不会具有不良影响，c）患者 与I.V.相比治疗。 这将是30例HIV相关患者的随机临床试验 腹泻，他们的医生需要静脉注射液 由于脱水的客观迹象。 他们将被随机 接收RB-or（n = 20）或静脉补液（n = 10），然后 在约翰·霍普金斯医院进行监测时，将获得此治疗 一般临床研究中心两天。 使用客观的度量 补液（体重，液体摄入和输出，串行血细胞比容和 总蛋白质测量和连续生物阻抗），成功率和 两种治疗方法的改善率将记录在案。 接受RB-OR但未补充水的患者将被放置 I.V.如果很高的患者可以成功补充水化 并通过RB-ors维护，将建立RB-or的实用性。